SUMO on the road to neurodegeneration

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1773, Issue 6, 2007, Pages 694-706

  Dorval, Véronique ^a   Fraser, Paul E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Neurodegenerative diseases; Neuronal inclusions; Proteasome; SUMO; Ubiquitin

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; ANDROGEN RECEPTOR; ATAXIN 1; CHAPERONE; DJ 1 PROTEIN; DYNAMIN; HUNTINGTIN; PROTEASOME; PROTEIN SUMO 2; PROTEIN SUMO 3; PROTEIN SUMO 4; SUMO 1 PROTEIN; SUMO PROTEIN; TAU PROTEIN; UBIQUITIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CELLULAR DISTRIBUTION; CONJUGATION; DEGENERATIVE DISEASE; DENTATORUBROPALLIDOLUYSIAN ATROPHY; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEURONAL INTRANUCLEAR INCLUSION DISEASE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN TARGETING; REVIEW; SHY DRAGER SYNDROME; SPINOCEREBELLAR DEGENERATION; SUMOYLATION;

ANIMALS; HUMANS; INTRANUCLEAR INCLUSION BODIES; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEURONS; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 34249733176     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2007.03.017     Document Type: Review

References (114)

1. Kersher O., Felberbaum R., and Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 22 (2006) 159-180
2. Su H.-L., and Li S.S.-L. Molecular features of human ubiquitin-like SUMO genes and their encoded proteins. Gene 296 (2002) 65-73
3. Bohren K.M., Nadkarni V., Song J.H., Gabbay K.H., and Owerbach D. A M55V polymorphism in a novel SUMO gene (SUMO-4) differentially activates heat shock transcription factors and is associated with susceptibility to type I diabetes mellitus. J. Biol. Chem. 279 (2004) 27233-27238
4. Melchior F., Schergaut M., and Pichler A. SUMO: ligases, isopeptidases and nuclear pores. Trends Biochem. Sci. 28 (2003) 612-618
5. Desterro J.M.P., Rodriguez M.S., Kemp G.D., and Hay R.T. Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. J. Biol. Chem. 274 (1999) 10618-10624
6. Desterro J.M.P., Thomson J., and Hay R.T. Ubch9 conjugates SUMO but not ubiquitin. FEBS Lett. 47 (1997) 297-300
7. Okuma T., Honda R., Ichikawa G., Tsumagari N., and Yasuda H. In vitro SUMO-1 modification requires two enzymatic steps, E1 and E2. Biochem. Biophys. Res. Commun. 254 (1999) 693-698
8. Rodriguez M.S., Dargemont C., and Hay R.T. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol. Chem. 276 (2001) 12654-12659
9. Lin D., Tatham M.H., Yu B., Kim S., Hay R.T., and Chen Y. Identification of a substrate recognition site on Ubc9. J. Biol. Chem. 277 (2002) 21740-21748
10. Tatham M.H., Jaffray E., Vaughan O.A., Desterro J.M.P., Botting C.H., Naismith J.H., and Hay R.T. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J. Biol. Chem. 276 (2001) 35368-35374
11. Cooper H.J., Tatham M.H., Jaffray E., Heath J.K., Lam T.T., Marshall A.G., and Hay R.T. Fourier transform ion cyclotron resonance mass spectrometry for the analysis of small ubiquitin-like modifier (SUMO) modification: identification of lysines in RanBP2 and SUMO targeted for modification during the E3 autoSUMOylation reaction. Anal. Chem. 77 (2005) 6310-6319
12. Wang H., Lim P.J., Yin C., Rieckher M., Vogel B.E., and Monteiro M.J. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum. Mol. Genet. 15 (2006) 1025-1041
13. Villagra N.T., Navascues J., Casafont I., Val-Bernal J.F., Lafarga M., and Berciano M.T. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains. Neurobiol. Dis. 21 (2006) 181-193
14. Gocke C.B., Yu H., and Kang J. Systematic identification and analysis of mammalian small ubiquitin-like modifier substrates. J. Biol. Chem. 280 (2005) 5004-5012
15. Rosas-Acosta G., Russell W.K., Deyrieux A., Russell D.H., and Wilson V.G. A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers. Mol. Cell. Proteomics 4 (2005) 56-72
16. Dorval V., and Fraser P.E. Small ubiquitin-like modifier (SUMO) modification of natively unfolded proteins tau and α-synuclein. J. Biol. Chem. 281 (2006) 9919-9924
17. Salinas S., Briancon-Marjollet A., Bossis G., Lopez M.A., Piechaczyk M., Jariel-Encontre I., Debant A., and Hipskind R.A. SUMOylation regulates nucleo-cytoplasmic shuttling of Elk-1. J. Cell Biol. 165 (2004) 767-773
18. Vertegaal A.C.O., Andersen J.S., Ogg S.C., Hay R.T., Mann M., and Lamond A.I. Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics. Mol. Cell. Proteomics 5 (2006) 2298-2310
19. Saitoh H., and Hinchey J. Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO2/3. J. Biol. Chem. 275 (2000) 6252-6258
20. Johnson E.S., and Gupta A.A. An E3-like factor that promotes SUMO conjugation to the yeast septins. Cell 106 (2001) 735-744
21. Kahyo T., Nishida T., and Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol. Cell 8 (2001) 713-718
22. Pichler A., Gast A., Seeler J.-S., Dejean A., and Melchior F. The nucleoporin RanBP2 has SUMO1 E3 ligase activity. Cell 108 (2002) 109-120
23. Kagey M.H., Melhuish T.A., and Wotton D. The polycomb protein Pc2 is a SUMO E3. Cell 113 (2003) 127-137
24. Weger S., Hammer E., and Heilbronn R. Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo. FEBS Lett. 579 (2005) 5007-5012
25. Morita Y., Kanei-Ishii C., Nomura T., and Ishii S. TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Mol. Biol. Cell 16 (2005) 5433-5444
26. Bossis G., and Melchior F. SUMO: regulating the regulator. Cell Div. 1 (2006) 349-357
27. Hietakangas V., Anckar J., Blomster H., Fugimoto M., Palvimo J.J., Nakai A., and Sistonen L. PDSM, a motif for phosphorylation-dependent SUMO modification. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 45-50
28. Bossis G., and Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol. Cell 21 (2006) 349-357
29. Reverter D., and Lima C.D. A basis for SUMO protease specificity provided by analysis of human Senp2 and a Senp2-SUMO complex. Structure 12 (2004) 1519-1531
30. Gong L., and Yeh E.T.H. Characterization of a family of nucleolar SUMO-specific proteases with preference for SUMO-2 or SUMO-3. J. Biol. Chem. 281 (2006) 15869-15877
31. Shen L.N., Dong C., Liu H., Naismith J.H., and Hay R.T. The structure of SENP1-SUMO2 complex suggests a structural basis for discrimination between SUMO paralogues during processing. Biochem. J. 397 (2006) 279-288
32. Di Bacco A., Ouyang J., Lee H.J., Catic A., Ploegh H., and Gill G. SUMO-specific proteases required for cell division. Mol. Cell. Biol. 26 (2006) 4489-4498
33. Mukhopadhyay D., Ayaydin F., Kolli N., Tan S.-H., Anan T., Kametaka A., Azuma Y., Wilkinson K.D., and Dasso M. SUSP1 antagonizes formation of highly SUMO2/3-conjugated species. J. Cell Biol. 174 (2006) 939-949
34. Ulrich H.D. Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol. 15 (2005) 525-532
35. Pichler A., Knipscheer P., Oberhofer E., van Dijk W.J., Körner R., Olsen J.V., Jentsch S., Melchior F., and Sixma T.K. SUMO modification of the ubiquitin-conjugating enzyme E2-25K. Nat. Struct. Mol. Biol. 12 (2005) 264-269
36. Boggio R., Colombo R., Hay R.T., Draetta G.F., and Chiocca S. A mechanism for inhibiting the SUMO pathway. Mol. Cell 16 (2004) 549-561
37. Bailey D., and O'Hare P. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling. Biochem. J. 392 (2005) 271-281
38. Rodriguez M.S., Desterro J.M.P., Lain S., Midgley C.A., Lane D.P., and Hay R.T. SUMO-1 modification activates the transcriptional response of p53. EMBO J. 18 (1999) 6455-6461
39. Poukka H., Karvonen U., Jänne O.A., and Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14145-14150
40. Desterro J.M.P., Rodriguez M.S., and Hay R.T. SUMO-1 modification of IκBα inhibits NF-κB activation. Mol. Cell 2 (1998) 233-239
41. Li S.-J., and Hochstrasser M. A new protease required for cell-cycle progression in yeast. Nature 398 (1999) 246-251
42. Hoege C., Pfander B., Moldovan G.L., Pyrowolakis G., and Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 419 (2002) 135-141
43. Denison C., Rudner A.D., Gerber S.A., Bakalarski C.E., Moazed D., and Gygi S.P. A proteomic strategy for gaining insights into protein sumoylation in yeast. Mol. Cell. Proteomics 4 (2005) 246-254
44. Wohlschlegel J.A., Johnson E.S., Reed S.I., and Yates J.R.I. Global analysis of protein sumoylation in Saccharomyces cerevisiae. J. Biol. Chem. 279 (2004) 45662-45668
45. Johnson E.S. Protein modification by SUMO. Annu. Rev. Biochem. 73 (2004) 355-382
46. Mishra R.K., Jatiani S.S., Kumar A., Simhadri V.R., Hosur R.V., and Mittal R. Dynamin interacts with members of the sumoylation machinery. J. Biol. Chem. 279 (2004) 31445-31454
47. Um J.W., and Chung K.C. Functional modulation of parkin through physical interaction with SUMO-1. J. Neurosci. Res. 84 7 (2006) 1543-1554
48. Takahashi H., Hatakeyama S., Saitoh H., and Nakayama K.-I. Noncovalent SUMO1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein. J. Biol. Chem. 280 (2005) 5611-5621
49. Zheng Z., Cai C., Omwancha J., Chen S.-Y., Baslan T., and Shemshedini L. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. J. Biol. Chem. 281 (2006) 4002-4012
50. Minty A., Dumont X., Kaghad M., and Caput D. Covalent modification of p73α by SUMO-1. Two hybrids screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J. Biol. Chem. 275 (2000) 36316-36323
51. Song J., Durrin L.K., Wilkinson T.A., Krontiris T.G., and Chen Y. Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14373-14378
52. Hannich J.T., Lewis A., Kroetz M.B., Li S.-J., Heide H., Emili A., and Hochstrasser M. Defining the SUMO-modified proteome by multiple approaches in Saccharomyces cerevisiae. J. Biol. Chem. 280 (2005) 4102-4110
53. Hecker C.-M., Rabiller M., Haglund K., Bayer P., and Dikic I. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 281 (2006) 16117-16127
54. Shen T.H., Lin H.-K., Scaglioni P.P., Yung T.M., and Pandolfi P.P. The mechanisms of PML-nuclear body formation. Mol. Cell 24 (2006) 331-339
55. Lin D.Y., Huang Y.S., Jeng J.C., Kuo H.Y., Chang C.C., Chao T.T., Ho C.C., Chen Y.C., Lin T.P., Fang H.I., Hung C.C., Suen C.S., Hwang M.J., Chang K.S., Maul G.G., and Shih H.M. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol. Cell 24 (2006) 341-354
56. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., and Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal cell death. Nature 431 (2004) 805-810
57. Slow E.J., Graham R.K., Osmand A.P., Devon R.S., Lu G., Deng Y., Pearson J., Vaid K., Bissada N., Wetzel R., Leavitt B.R., and Hayden M.R. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11402-11407
58. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., and Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300 (2003) 486-489
59. 1-42 into globular neurotoxins. Biochemistry 42 (2003) 12749-12760
60. Ciechanover A., and Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40 (2003) 427-446
61. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
62. Leroy E., Boyer R., Auburger G., Leube B., Ulm G., Mezey E., Harta G., Brownstein M.J., Jonnalagada S., Chernova T., Dehejia A., Lavedan C., Gasser T., Steinbach P.J., Wilkinson K.D., and Polymeropoulos M.H. The ubiquitin pathway in Parkinson's disease. Nature 395 (1998) 451-452
63. Gatchel J.R., and Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev., Genet. 6 (2005) 743-755
64. Watase K., Weeber E.J., Xu B., Antalffy B., Yuva-Paylor L., Hashimoto K., Kano M., Atkinson R., Sun Y., Armstrong D.L., Sweatt J.D., Orr H.T., Paylor R., and Zoghbi H.Y. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34 (2002) 905-919
65. Yoo S.Y., Pennesi M.E., Weeber E.J., Xu B., Atkinson R., Chen S., Armstrong D.L., Wu S.M., Sweatt J.D., and Zoghbi H.Y. SCA7 knockin mice model human SCA7 and reveal gradual accumulation of mutant ataxin-7 in neurons and abnormalities in short-term plasticity. Neuron 6 (2003) 383-401
66. Bowman A.B., Yoo S.Y., Dantuma N.P., and Zoghbi H.Y. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum. Mol. Genet. 14 (2005) 679-691
67. Ueda H., Goto J., Hashida H., Lin X., Oyanagi K., Kawano H., Zoghbi H.Y., Kanazawa I., and Okazawa H. Enhanced SUMOylation in polyglutamine disease. Biochem. Biophys. Res. Commun. 293 (2002) 307-313
68. Terashima T., Kawai H., Fujitani M., Maeda K., and Yasuda H. SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Neuroreport 13 (2002) 2359-2364
69. Pountney D.L., Huang Y., Burns R.J., Haan E., Thompson P.D., Blumbergs P.C., and Gai W.P. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp. Neurol. 184 (2003) 436-446
70. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.-Z., Cattaneo E., Pandolfi P.P., Thompson L.M., and Marsh J.L. SUMO modification of Huntingtin and Huntington's disease pathology. Science 304 (2004) 100-104
71. Riley B.E., Zoghbi H.Y., and Orr H.T. SUMOylation of the polyglutamine repeat protein, ataxin-1, is dependent on a functional nuclear localization signal. J. Biol. Chem. 280 (2005) 21942-21948
72. Chan H.Y., Warrick J.M., Andriola I., Merry D., and Bonini N.M. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. 11 (2002) 2895-2904
73. Besnault-Mascard L., Leprince C., Auffredou M.T., Meunier B., Bourgeade M.F., Camonis J., Lorenzo H.K., and Vazquez A. Caspase-8 sumoylation is associated with nuclear localization. Oncogene 24 (2005) 3268-3273
74. Shirakura H., Hayashi N., Ogino S., Tsuruma K., Uehara T., and Nomura Y. Caspase recruitment domain of procaspase-2 could be a target for SUMO-1 modification through Ubc9. Biochem. Biophys. Res. Commun. 331 (2005) 1007-1015
75. Hayashi N., Shirakura H., Uehara T., and Nomura Y. Relationship between SUMO-1 modification of caspase-7 and its nuclear localization in human neuronal cells. Neurosci. Lett. 397 (2006) 5-9
76. Huang T.T., Wuerzberger-Davis S.M., Wu Z.-H., and Miyamoto S. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 115 (2003) 565-576
77. Taylor J., Grote S.K., Xia J., Vandelft M., Graczyk J., Ellerby L.M., La Spada A.R., and Truant R. Ataxin-7 can export from the nucleus via a conserved exportin-dependent signal. J. Biol. Chem. 281 (2006) 2730-2739
78. Gill G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev. 13 (2003) 108-113
79. Yasuda S., Inoue K., Hirabayashi M., Higashiyama H., Yamamoto Y., Fuyuhiro H., Komure O., Tanaka F., Sobue G., Tsuchiya K., Hamada K., Sasaki H., Takeda K., Ichijo H., and Kakizuka A. Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies. Genes Cells 4 (1999) 743-756
80. Takahashi-Fujigasaki J., Arai K., Funata N., and Fujigasaki H. SUMOylation substrates in neuronal intranuclear inclusion disease. Neuropathol. Appl. Neurobiol. 32 (2006) 92-100
81. Steffan J.S., Kazantsev A., Spasic-Boskovic O., Greenwald M., Zhu Y.-Z., Gohler H., Wanker E.E., Bates G.P., Housman D.E., and L.M. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 6763-6768
82. Shalizi A., Gaudilliere B., Yuan Z., Stegmuller J., Shirogane T., Ge Q., Tan Y., Schulman B., Harper J.W., and Bonni A. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 311 (2006) 1012-1017
83. Sung J.H., Ramirez-Lassepas M., Mastri A.R., and Larkin S.M. An unusual degenerative disorder of neurons associated with a novel intranuclear hyaline (neuronal intranuclear hyaline inclusion disease). A clinicopathological study of a case. J. Neuropathol. Exp. Neurol. 39 (1980) 107-130
84. Kimber T.S., Blumbergs P.C., Rice J.P., Hallpike J.F., Edis R., Thompson P.D., and Suthers G. Familial neuronal intranuclear inclusion disease with ubiquitin positive inclusions. J. Neurol. Sci. 160 (1998) 33-40
85. McFadden K., Hamilton R.L., Insalaco S.J., Lavine L., Al-Mateen M., Wang G., and Wiley C.A. Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child. J. Neuropathol. Exp. Neurol. 64 (2005) 545-552
86. Lieberman A.P., Robitaille Y., Trojanowski J.Q., Dickson D.W., and Fischbeck K.H. Polyglutamine-containing aggregates in neuronal intranuclear inclusion disease. Lancet 351 (1998) 884
87. Lieberman A.P., Trojanowski J.Q., Leonard D.G., Chen K.L., Barnett J.-L., Leverenz J.B., Bird T.D., Robitaille Y., Malandrini A., and Fischbeck K.H. Ataxin 1 and ataxin 3 in neuronal intranuclear inclusion disease. Ann. Neurol. 46 (1999) 271-273
88. 3-induced PML or PML/retinoic acid receptor α degradation. J. Exp. Med. 1361-1371 (2001) 12
89. Lafarga M., Berciano M.T., Pena E., Mayo I., Castaño E.M., Bohmann D., Rodrigues J.P., Tavanez J.P., and Carmo-Fonseca M. Calstosome: a subtype of nuclear body enriched in 19S and 20S proteasomes, ubiquitin, and protein substrates of proteasome. Mol. Biol. Cell 13 (2002) 2771-2782
90. Mackenzie I.R., Baker M., West G., Woulfe J., Qadi N., Gass J., Cannon A., Adamson J., Feldman H., Lindholm C., Melquist S., Pettman R., Sadovnick A.D., Dwosh E., Whiteheart S.W., Hutton M., and Pickering-Brown S.M. A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. Brain 129 (2006) 853-867
91. Pountney D.L., Chegini F., Shen X., Blumbergs P.C., and Gai W.P. SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy. Neurosci. Lett. 381 (2005) 74-79
92. Um J.W., Min D.S., Rhim H., Kim J., Paik S.R., and Chung K.C. Parkin ubiquitinates and promotes the degradation of RanBP2. J. Biol. Chem. 281 (2006) 3595-3603
93. Takahashi K., Taira T., Niki T., Seino C., Iguchi-Ariga S.M.M., and Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASxα to the receptor. J. Biol. Chem. 276 (2001) 37556-37563
94. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M.M., Takahashi K., and Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5 (2004) 213-218
95. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (2003) S26-S38
96. Shinbo Y., Niki T., Taira T., Ooe H., Takahashi-Niki K., Maita C., Seino C., Iguchi-Ariga S.M.M., and Ariga H. Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ. 13 (2006) 96-108
97. Rizzu P., Hinkle D.A., Zhukareva V., Bonifati V., Severijnen L.-A., Martinez D., Ravid R., Kamphorst W., Eberwine J.H., Lee V.M.-Y., Trojanowski J.Q., and Heutink P. DJ-1 colocalizes with tau inclusions: a link between parkinsonism and dementia. Ann. Neurol. 55 (2004) 113-118
98. Neumann M., Müller V., Görner K., Kretzschmar H.A., Haass C., and Kahle P.J. Pathological properties of the Parkinson's disease-associated protein DJ-1 in α-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol. 107 (2004) 489-496
99. Wolfe M.S. The γ-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45 (2006) 7931-7939
100. Li Y., Wang H., Wang S., Quon D., Liu Y.-W., and Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 259-264
101. Dorval V., Mazzella M.J., Mathews P.M., Hay R.T., and Fraser P.E. Modulation of Aβ generation by small ubiquitin-like modifiers does not require conjugation to target proteins. Biochem. J. 404 2 (2007) 309-316
102. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., and Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 4051-4055
103. Mori H., Kondo J., and Ihara Y. Ubiquitin is a component of paired-helical filaments in Alzheimer's disease. Science 235 (1987) 1641-1644
104. Perry G., Friedman R., Shaw G., and Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer's disease brains. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3033-3036
105. Johnson F., and Giulivi C. Superoxide dismutases and their impact upon human health. Mol. Aspects Med. 26 (2005) 340-352
106. Zhou W., Ryan J.J., and Zhou H. Global analyses of sumoylated proteins in Saccharomyces cerevisiae. Induction of protein sumoylation by cellular stresses. J. Biol. Chem. 279 (2004) 32262-32268
107. Wykoff D.D., and O'Shea E.K. Identification of sumoylated proteins by systematic immunoprecipitation of the budding yeast. Mol. Cell. Proteomics 4 (2005) 73-83
108. Fei E., Jia N., Yan M., Ying Z., Sun Q., Wang H., Zhang T., Ma X., Ding H., Yao X., Shi Y., and Wang G. SUMO-1 modification increases human SOD1 stability and aggregation. Biochem. Biophys. Res. Commun. 347 (2006) 406-412
109. Chen Z., and Pickart C.M. A 25-kilodalton ubiquitin carrier protein (E2) catalyzes multi-ubiquitin chain synthesis via lysine 48 of ubiquitin. J. Biol. Chem. 265 (1990) 21835-21842
110. Kalchman M.A., Graham R.K., Xia G., Koide H.B., Hodgson J.G., Graham K.C., Goldberg Y.P., Gietz R., Pickart C.M., and Hayden M.R. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J. Biol. Chem. 271 (1999) 19385-19394
111. Chyung J.H., and Selkoe D. Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid β-protein at the cell surface. J. Biol. Chem. 278 (2003) 51035-51043
112. Meriin A.B., and Sherman M.Y. Role of molecular chaperones in neurodegenerative disorders. Int. J. Hypertherm. 21 (2005) 403-419
113. Zhao Y., Kwon S.W., Anselmo A., Kaur K., and White M.A. Broad spectrum identification of cellular small ubiquitin-related modifier (SUMO) substrate proteins. J. Biol. Chem. 279 (2004) 20999-21002
114. Panse V.G., Hardeland U., Werner T., Kuster B., and Hurt E. A proteome-wide approach identifies sumoylated substrate proteins in yeast. J. Biol. Chem. 279 (2004) 41346-41351